Clinical trials: Breast Cancer
Breast Cancer
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This two-part study is composed of two stages: a Phase Ib stage consisting of a dose-escalation phase and an expansion phase; and a Phase II, randomized, placebo-controlled, double-blind, multicenter stage.
- Trial name
- NCT04298918
- Testing
- Venetoclax, Trastuzumab emtansine
- Where
- 3 sites in Australia, South Korea
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
The general aim of this study is to investigate the efficacy and safety of afatinib (BIBW 2992) alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who progress on afatinib monotherapy within this…
- Trial name
- NCT01271725
- Testing
- Vinorelbine 25 mg/m2 weekly, Afatinib 40mg once daily (OD), Paclitaxel 80 mg/m2 weekly
- Where
- 27 sites in Hong Kong, India and 4 more
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasms
The Digital Breast Tomosynthesis Trial in Bergen
Compare synthetic mammography+digital breast tomosynthesis (SM+DBT) with digital mammography (DM) as a screening tool for women aged 50-69 years, invited to participate in the Norwegian Breast Cancer Screening Program at the…
- Trial name
- TOBE (NCT02835625)
- Testing
- Synthetic Mammography + Digital Breast Tomosynthesis, Digital mammography
- Where
- 2 sites in Norway
- Volunteers
- 29,453 people, healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Breast Cancer, Ovarian Cancer
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma
- Trial name
- NCT01831089
- Testing
- PM01183 + paclitaxel +/- bevacizumab
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Lung Cancer, Breast Cancer
Measuring and Improving the Safety of Test Result Follow-Up
Improving communication is foundational to improving patient safety. Electronic health records (EHRs) can improve communication, but also introduce unique vulnerabilities.
- Conditions
- Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT04166240
- Testing
- SAFER TRACKS Intervention
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- VA Office of Research and Development
Premenopausal Breast Cancer
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
The purpose of this survey is to evaluate the safety in patients with premenopausal breast cancer receiving Leuprorelin in the routine clinical setting.
- Trial name
- NCT03209518
- Testing
- Leuprorelin acetate
- Where
- Japan
- Volunteers
- 312 people
- Sponsor
- Takeda
Breast Cancer
Patient Controlled Tissue Expansion for Breast Reconstruction
This study is designed to compare the performance and safety of the AirXpander tissue expander to standard saline expanders in patients undergoing two-stage breast reconstruction following mastectomy.
- Trial name
- XPAND (NCT01425268)
- Testing
- AeroForm Tissue Expansion, Saline Tissue Expansion
- Where
- 17 sites in United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- AirXpanders, Inc.
Breast Cancer
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable and unresectable HER2+ (stage IIa-IIIb) breast cancer
- Trial name
- NCT00617942
- Testing
- Cohort 1 neo-adjuvant, Cohort 2 neo-adjuvant, Cohort 1 adjuvant
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- William Sikov MD
Breast Carcinoma
Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
This clinical trial studies the use of contrast-enhanced ultrasound (CEUS) in estimating tissue pressure in patients with breast cancer. Diagnostic procedures, such as CEUS, may help estimate tissue pressure noninvasively.
- Trial name
- NCT04721886
- Testing
- Ultrasonsgraphy, Perflutren Lipid Microcpheres, Contrast - Enhanced Ultrasound
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Thomas Jefferson University
Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00382070
- Testing
- Letrozole
- Where
- 806 sites in United States, Canada and 1 more
- Volunteers
- 3,966 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
This is a two-arm, randomized, double-blind, multicenter, pre-operative study to evaluate the effect of combining letrozole and GDC-0032 (also known as taselisib) versus letrozole and placebo in postmenopausal women with estrogen…
- Trial name
- NCT02273973
- Testing
- Letrozole, Taselisib
- Where
- 117 sites in United States, Australia and 20 more
- Volunteers
- 334 people
- Sponsor
- Genentech, Inc.
Breast Cancer
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
- Trial name
- NCT00320541
- Testing
- gemcitabine, paclitaxel, bevacizumab
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT
The purpose of this study is to evaluate the role of technologist-performed whole breast ultrasound for detecting breast cancer in the screening population of women with dense breasts.
- Trial name
- DBTUST (NCT02643966)
- Testing
- Whole breast ultrasound
- Where
- 2 sites in United States
- Volunteers
- 6,266 people, healthy volunteers welcome
- Sponsor
- Wendie Berg
Neoplasms
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02122146
- Testing
- PF-06664178
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Breast Neoplasms
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (Herceptin®)…
- Trial name
- NCT01125566
- Testing
- BIBW 2992, trastuzumab, vinorelbine
- Where
- 207 sites in United States, Argentina and 36 more
- Volunteers
- 508 people
- Sponsor
- Boehringer Ingelheim
Metastatic Breast Cancer
Fresolimumab and Radiotherapy in Metastatic Breast Cancer
The purpose of this study is to test safety of combining fresolimumab and local radiotherapy and to see if the combination can achieve tumor regression.
- Trial name
- NCT01401062
- Testing
- Fresolimumab, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Weill Medical College of Cornell University
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer
This is an open-label, multi-center, non-randomized study of the safety and tolerability of the combination of T-DM1 plus docetaxel for the treatment of participants with metastatic breast cancer (MBC) and of T-DM1 plus docetaxel…
- Trial name
- NCT00934856
- Testing
- Docetaxel, Pertuzumab, Trastuzumab emtansine
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent activity in previously treated advanced breast cancer.
- Trial name
- NCT00632541
- Testing
- Sorafenib, Bevacizumab, Imaging
- Where
- 10 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hoosier Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.